Quick Answer
Emergent BioSolutions Inc. reported Long Term Debt of $589.70 million for the year ending 2025.
- Emergent BioSolutions Inc. showed a decrease of -15.8% in Long Term Debt from 2024 to 2025.
- This data is from Emergent BioSolutions Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2010 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $29.07 million | Q3 2011: $48.87 million | Q1 2012: $57.59 million | Q2 2012: $58.14 million | Q3 2012: $58.87 million | Q1 2013: $57.19 million | Q2 2013: $56.07 million | Q3 2013: $54.95 million | Q4 2013: $62.00 million | Q1 2014: $251.00 million | Q2 2014: $251.00 million | Q3 2014: $251.00 million | Q1 2015: $251.00 million | Q2 2015: $253.00 million | Q3 2015: $253.00 million | Q1 2016: $247.19 million | Q2 2016: $247.39 million | Q3 2016: $247.79 million | Q1 2017: $248.39 million | Q2 2017: $248.69 million | Q3 2017: $248.99 million | Q1 2018: $13.47 million | Q2 2018: $13.48 million | Q3 2018: $13.50 million | Q1 2019: $732.40 million | Q2 2019: $830.40 million | Q3 2019: $813.30 million | Q1 2020: $762.90 million | Q2 2020: $758.10 million | Q3 2020: $848.50 million | Q1 2021: $833.10 million | Q2 2021: $825.20 million | Q3 2021: $817.30 million | Q1 2022: $801.50 million | Q2 2022: $793.60 million | Q3 2022: $1.03 billion | Q1 2023: $447.70 million | Q2 2023: $448.00 million | Q3 2023: $448.20 million | Q1 2024: $446.70 million | Q2 2024: $447.00 million | Q3 2024: $661.80 million | Q4 2024: $663.70 million | Q1 2025: $665.70 million | Q2 2025: $667.80 million | Q3 2025: $663.10 million.
- Over the full 17 years of available data (2010 to 2025), Emergent BioSolutions Inc.'s Long Term Debt has grown by 1,850.1%.
- Historical annual values: Fiscal year 2025: $589.70 million | Fiscal year 2024: $700.00 million | Fiscal year 2024: $663.70 million | Fiscal year 2023: $446.50 million | Fiscal year 2022: $448.50 million | Fiscal year 2021: $809.40 million | Fiscal year 2020: $841.00 million | Fiscal year 2019: $798.40 million | Fiscal year 2018: $784.50 million | Fiscal year 2017: $13.50 million | Fiscal year 2016: $248.09 million | Fiscal year 2015: $246.89 million | Fiscal year 2014: $251.00 million | Fiscal year 2013: $62.00 million | Fiscal year 2012: $58.30 million | Fiscal year 2011: $54.09 million | Fiscal year 2010: $30.24 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: